HomeProductsBioactive CompoundsJAK/STAT SignalingJAKMubritinib
Chemical structure of CAS 366017-09-6

Mubritinib

CAS No.366017-09-6
MDL No.MFCD09954135
MFC25H23F3N4O2
MW468.50
InChI KeyZTFBIUXIQYRUNT-MDWZMJQESA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

Mubritinib has been studied in trials for the treatment of Lung Neoplasm, Renal Neoplasm, Breast Neoplasm, Ovarian Neoplasm, and Pancreatic Neoplasm.

CAS No.366017-09-6
Product NameMubritinib

Biological Targets

ERBB2

Associated Conditions

pancreatic neoplasm·ovarian neoplasm·kidney neoplasm·lung neoplasm·breast neoplasm
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.

The Biochemical journal • Vol. 451, Issue 2 • 2013
PMID: 23398362DOI: 10.1042/BJ20121418

Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity.

Nature biotechnology • Vol. 29, Issue 11 • 2011
PMID: 22037377PMC: PMC3230241DOI: 10.1038/nbt.2017

Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo.

International journal of urology : official journal of the Japanese Urological Association • Vol. 13, Issue 5 • 2006
PMID: 16771730DOI: 10.1111/j.1442-2042.2006.01342.x

Documentation